Shopping Cart 0
Cart Subtotal
AED 0

AC Immune SA (ACIU) - Financial and Strategic SWOT Analysis Review

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 459

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 918

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 1376

Details

AC Immune SA (ACIU)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description-A detailed description of the company's operations and business divisions.

- Corporate strategy-Analyst's summarization of the company's business strategy.

- SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

- Company history-Progression of key events associated with the company.

- Major products and services-A list of major products, services and brands of the company.

- Key competitors-A list of key competitors to the company.

- Key employees-A list of the key executives of the company.

- Executive biographies-A brief summary of the executives' employment history.

- Key operational heads-A list of personnel heading key departments/functions.

- Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

- Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

AC Immune SA (AC Immune) is a biopharmaceutical company that discovers designs and develops proprietary medicines to prevent, diagnose and treat neurodegenerative diseases associated with protein misfolding. The company develops drugs based on its two proprietary technology platforms: SupraAntigen and Morphomer. Its technology platforms help the company to design, discover and develop antibodies, small molecules and vaccines. AC Immune's product pipeline includes nine therapeutic product candidates and three diagnostic product candidates. The company's lead product candidate, crenezumab is being studied in preventive trial of cognitive healthy individuals who are at risk of developing familial Alzheimer's Disease (fAD). AC Immune is headquartered in Lausanne, Switzerland.

AC Immune SA Key Recent Developments

Nov 13,2019: AC Immune Q3 2019 financial results and business update

Oct 24,2019: AC Immune to host key opinion leader event: 'Untangling' Tau pathology to treat Alzheimer's and Neurodegenerative Diseases

Aug 14,2019: AC Immune reports q2 2019 financial results, business and clinical update

Jun 28,2019: AC Immune announces election of new chairman of the board at annual general meeting

Jun 27,2019: AC Immune to host key opinion leader meeting on treating Alzheimer's in Down Syndrome

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1-About the Company

AC Immune SA-Key Facts

AC Immune SA-Key Employees

AC Immune SA-Key Employee Biographies

AC Immune SA-Major Products and Services

AC Immune SA-History

AC Immune SA-Company Statement

AC Immune SA-Locations And Subsidiaries

Head Office

Section 2-Company Analysis

Company Overview

AC Immune SA-Business Description

R&D Overview

AC Immune SA-Corporate Strategy

AC Immune SA-SWOT Analysis

SWOT Analysis-Overview

AC Immune SA-Strengths

AC Immune SA-Weaknesses

AC Immune SA-Opportunities

AC Immune SA-Threats

AC Immune SA-Key Competitors

Section 3-Company Financial Ratios

Financial Ratios-Capital Market Ratios

Financial Ratios-Annual Ratios

Performance Chart

Financial Performance

Financial Ratios-Interim Ratios

Financial Ratios-Ratio Charts

Section 4-Company's Lifesciences Financial Deals and Alliances

AC Immune SA, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020

AC Immune SA, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020

AC Immune SA, Recent Deals Summary

Section 5-Company's Recent Developments

Nov 13, 2019: AC Immune Q3 2019 financial results and business update

Oct 24, 2019: AC Immune to host key opinion leader event: 'Untangling' Tau pathology to treat Alzheimer's and Neurodegenerative Diseases

Aug 14, 2019: AC Immune reports q2 2019 financial results, business and clinical update

Jun 28, 2019: AC Immune announces election of new chairman of the board at annual general meeting

Jun 27, 2019: AC Immune to host key opinion leader meeting on treating Alzheimer's in Down Syndrome

May 15, 2019: AC Immune announces Q1 2019 financial results

Apr 01, 2019: AC Immune to Present at the H.C. Wainwright Global Life Sciences Conference

Mar 21, 2019: AC Immune Reports Full-Year 2018 Financial Results and Provides Business Update

Feb 07, 2019: AC Immune makes two appointments to executive committee to accelerate product development

Jan 03, 2019: AC Immune names Dr. Marie Kosco-Vilbois as Chief Scientific Officer

Section 6-Appendix

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer


List Of Figure

List of Figures

AC Immune SA, Performance Chart (2014-2018)

AC Immune SA, Ratio Charts

AC Immune SA, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020

AC Immune SA, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020


List Of Table

List of Tables

AC Immune SA, Key Facts

AC Immune SA, Key Employees

AC Immune SA, Key Employee Biographies

AC Immune SA, Major Products and Services

AC Immune SA, History

AC Immune SA, Key Competitors

AC Immune SA, Ratios based on current share price

AC Immune SA, Annual Ratios

AC Immune SA, Annual Ratios (Cont...1)

AC Immune SA, Interim Ratios

AC Immune SA, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020

AC Immune SA, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020

AC Immune SA, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

AC Immune SA, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts


Companies

Novartis AG

Axon Neurosciences

Araclon Biotech

AbbVie Holdings SAS

Company Profile

Company Profile Title

AC Immune SA (ACIU)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description-A detailed description of the company's operations and business divisions.

- Corporate strategy-Analyst's summarization of the company's business strategy.

- SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

- Company history-Progression of key events associated with the company.

- Major products and services-A list of major products, services and brands of the company.

- Key competitors-A list of key competitors to the company.

- Key employees-A list of the key executives of the company.

- Executive biographies-A brief summary of the executives' employment history.

- Key operational heads-A list of personnel heading key departments/functions.

- Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

- Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

AC Immune SA (AC Immune) is a biopharmaceutical company that discovers designs and develops proprietary medicines to prevent, diagnose and treat neurodegenerative diseases associated with protein misfolding. The company develops drugs based on its two proprietary technology platforms: SupraAntigen and Morphomer. Its technology platforms help the company to design, discover and develop antibodies, small molecules and vaccines. AC Immune's product pipeline includes nine therapeutic product candidates and three diagnostic product candidates. The company's lead product candidate, crenezumab is being studied in preventive trial of cognitive healthy individuals who are at risk of developing familial Alzheimer's Disease (fAD). AC Immune is headquartered in Lausanne, Switzerland.

AC Immune SA Key Recent Developments

Nov 13,2019: AC Immune Q3 2019 financial results and business update

Oct 24,2019: AC Immune to host key opinion leader event: 'Untangling' Tau pathology to treat Alzheimer's and Neurodegenerative Diseases

Aug 14,2019: AC Immune reports q2 2019 financial results, business and clinical update

Jun 28,2019: AC Immune announces election of new chairman of the board at annual general meeting

Jun 27,2019: AC Immune to host key opinion leader meeting on treating Alzheimer's in Down Syndrome

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

READ MORE

Scope

Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1-About the Company

AC Immune SA-Key Facts

AC Immune SA-Key Employees

AC Immune SA-Key Employee Biographies

AC Immune SA-Major Products and Services

AC Immune SA-History

AC Immune SA-Company Statement

AC Immune SA-Locations And Subsidiaries

Head Office

Section 2-Company Analysis

Company Overview

AC Immune SA-Business Description

R&D Overview

AC Immune SA-Corporate Strategy

AC Immune SA-SWOT Analysis

SWOT Analysis-Overview

AC Immune SA-Strengths

AC Immune SA-Weaknesses

AC Immune SA-Opportunities

AC Immune SA-Threats

AC Immune SA-Key Competitors

Section 3-Company Financial Ratios

Financial Ratios-Capital Market Ratios

Financial Ratios-Annual Ratios

Performance Chart

Financial Performance

Financial Ratios-Interim Ratios

Financial Ratios-Ratio Charts

Section 4-Company's Lifesciences Financial Deals and Alliances

AC Immune SA, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020

AC Immune SA, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020

AC Immune SA, Recent Deals Summary

Section 5-Company's Recent Developments

Nov 13, 2019: AC Immune Q3 2019 financial results and business update

Oct 24, 2019: AC Immune to host key opinion leader event: 'Untangling' Tau pathology to treat Alzheimer's and Neurodegenerative Diseases

Aug 14, 2019: AC Immune reports q2 2019 financial results, business and clinical update

Jun 28, 2019: AC Immune announces election of new chairman of the board at annual general meeting

Jun 27, 2019: AC Immune to host key opinion leader meeting on treating Alzheimer's in Down Syndrome

May 15, 2019: AC Immune announces Q1 2019 financial results

Apr 01, 2019: AC Immune to Present at the H.C. Wainwright Global Life Sciences Conference

Mar 21, 2019: AC Immune Reports Full-Year 2018 Financial Results and Provides Business Update

Feb 07, 2019: AC Immune makes two appointments to executive committee to accelerate product development

Jan 03, 2019: AC Immune names Dr. Marie Kosco-Vilbois as Chief Scientific Officer

Section 6-Appendix

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer


List Of Figure

List of Figures

AC Immune SA, Performance Chart (2014-2018)

AC Immune SA, Ratio Charts

AC Immune SA, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020

AC Immune SA, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020


List Of Table

List of Tables

AC Immune SA, Key Facts

AC Immune SA, Key Employees

AC Immune SA, Key Employee Biographies

AC Immune SA, Major Products and Services

AC Immune SA, History

AC Immune SA, Key Competitors

AC Immune SA, Ratios based on current share price

AC Immune SA, Annual Ratios

AC Immune SA, Annual Ratios (Cont...1)

AC Immune SA, Interim Ratios

AC Immune SA, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020

AC Immune SA, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020

AC Immune SA, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

AC Immune SA, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts


Companies

Novartis AG

Axon Neurosciences

Araclon Biotech

AbbVie Holdings SAS